• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Friday's After-Market Session

    11/17/23 4:31:08 PM ET
    $ACRX
    $BBLG
    $CYTO
    $DMTK
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Industrial Specialties
    Health Care
    Get the next $ACRX alert in real time by email

    Gainers

    • Forte Biosciences (NASDAQ:FBRX) shares increased by 11.8% to $0.5 during Friday's after-market session. Today's trading volume for this security ended up closing at 287.3K shares, which is 905.6 percent of its average volume over the last 100 days. The company's market cap stands at $18.1 million. As per the news, the Q3 earnings report came out 4 days ago.
    • Telesis Bio (NASDAQ:TBIO) shares rose 10.81% to $0.41. Today's trading volume for this security ended up closing at 481.1K shares, which is 1248.9 percent of its average volume over the last 100 days. The market value of their outstanding shares is at $12.2 million. As per the press release, Q3 earnings came out 4 days ago.
    • AcelRx Pharmaceuticals (NASDAQ:ACRX) stock moved upwards by 8.16% to $0.53. The company's market cap stands at $8.8 million.
    • DermTech (NASDAQ:DMTK) stock increased by 7.33% to $1.61. The market value of their outstanding shares is at $55.1 million.
    • Renalytix (NASDAQ:RNLX) stock rose 7.04% to $0.59. The market value of their outstanding shares is at $28.9 million. As per the press release, Q1 earnings came out 3 days ago.
    • IN8bio (NASDAQ:INAB) shares increased by 6.0% to $0.96. The market value of their outstanding shares is at $30.7 million.

    Losers

    • Nautilus Biotechnology (NASDAQ:NAUT) stock declined by 10.5% to $2.71 during Friday's after-market session. The market value of their outstanding shares is at $338.8 million.
    • OpGen (NASDAQ:OPGN) stock decreased by 9.83% to $0.41. The market value of their outstanding shares is at $4.5 million. The company's, Q3 earnings came out 3 days ago.
    • Bone Biologics (NASDAQ:BBLG) stock decreased by 9.76% to $0.55. Trading volume for this security closed at 544.9K, accounting for 54.6% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $1.7 million. The company's, Q3 earnings came out 3 days ago.
    • ProSomnus (NASDAQ:OSA) stock declined by 8.03% to $0.46. The company's market cap stands at $7.5 million.
    • Kintara Therapeutics (NASDAQ:KTRA) shares declined by 7.63% to $0.34. As per the press release, Q1 earnings came out 4 days ago.
    • Altamira Therapeutics (NASDAQ:CYTO) stock fell 7.15% to $0.26. Today's trading volume for this security ended up closing at 14.6 million shares, which is 1359.1 percent of its average volume over the last 100 days. The company's market cap stands at $2.0 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ACRX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ACRX
    $BBLG
    $CYTO
    $DMTK

    CompanyDatePrice TargetRatingAnalyst
    Forte Biosciences Inc.
    $FBRX
    11/25/2025$65.00Outperform
    Evercore ISI
    Forte Biosciences Inc.
    $FBRX
    8/18/2025$75.00Buy
    Guggenheim
    Forte Biosciences Inc.
    $FBRX
    1/21/2025Buy
    TD Cowen
    Nautilus Biotechnology Inc.
    $NAUT
    12/5/2024$1.75Neutral → Sell
    Goldman
    Nautilus Biotechnology Inc.
    $NAUT
    6/27/2024$6.00Buy
    Guggenheim
    Nautilus Biotechnology Inc.
    $NAUT
    6/3/2024$3.00Hold
    Jefferies
    Forte Biosciences Inc.
    $FBRX
    4/8/2024$2.75Neutral → Buy
    Ladenburg Thalmann
    IN8bio Inc.
    $INAB
    3/18/2024$7.50Buy
    Laidlaw
    More analyst ratings

    $ACRX
    $BBLG
    $CYTO
    $DMTK
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Nautilus Biotechnology Announces Baylor College of Medicine as First Early Access Program Customer for Voyager Platform

    • Baylor selects the Nautilus Voyager™ Platform, now available through Early Access Program, for development of a first-in-class computational multi-omics toolkit• NIH-funded project leverages collaborators' expertise in single-molecule proteomics and protein isoform quantification to advance high-resolution cancer isoform analysis SEATTLE, March 18, 2026 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ:NAUT), a company pioneering single-molecule proteome analysis, today announced Baylor College of Medicine as the first customer of Nautilus' Iterative Mapping Early Access Program. Through a National Institutes of Health (NIH) U01-funded study, Baylor will leverage Nautilus' novel

    3/18/26 8:00:00 AM ET
    $NAUT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Forte Biosciences, Inc. Reports Inducement Grants Under Nasdaq Listing Rules

    Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ:FBRX), a clinical-stage biopharmaceutical company focused on developing FB102, which is a proprietary anti-CD122 monoclonal antibody therapeutic candidate with potentially broad autoimmune and autoimmune-related indications, today announced the issuance of equity inducement awards as required by the Nasdaq Stock Market Rules. In accordance with NASDAQ Listing Rule 5635(c)(4), the Compensation Committee of Forte's Board of Directors approved the grant of equity awards in the form of options to purchase an aggregate total of 25,000 shares of common stock to new non-executive employees as a material inducement to such individuals accepting

    3/17/26 4:01:00 PM ET
    $FBRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    IN8bio Reports Fourth Quarter and Full-Year 2025 Financial Results - Highlights Durable Survival Improvements in Glioblastoma, Advancing Pipeline and Strengthened Financial Position for 2026

    Presented updated glioblastoma ("GBM") data demonstrating durable survival and a favorable safety profile across Phase 1 and Phase 2 programs, with repeat dosing of DeltEx™ Drug-Resistant Immunotherapy γδ T cells ("DRI") nearly doubling median progression-free survival ("mPFS") to 13.0 months versus 6.6 months in a contemporaneous standard-of-care control cohort (+97%) Closed initial $20.1 million tranche of a private placement of up to $40.2 million in gross proceeds; net proceeds extend cash runway into the first half of 2027 and support advancement of the gamma-delta T cell engager ("TCE") platform Continued advancement of gamma-delta T cell therapies and TCE pipeline across oncology an

    3/12/26 4:01:00 PM ET
    $INAB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ACRX
    $BBLG
    $CYTO
    $DMTK
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CEO, President, and Secretary Patel Sujal M bought $65,238 worth of shares (25,000 units at $2.61), increasing direct ownership by 0.24% to 10,366,721 units (SEC Form 4)

    4 - Nautilus Biotechnology, Inc. (0001808805) (Issuer)

    3/4/26 6:37:20 PM ET
    $NAUT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    CHIEF FINANCIAL OFFICER Riley Antony A bought $254,833 worth of shares (9,680 units at $26.33), converted options into 375 shares and covered exercise/tax liability with 154 shares, increasing direct ownership by 31% to 41,741 units (SEC Form 4)

    4 - Forte Biosciences, Inc. (0001419041) (Issuer)

    1/2/26 4:04:43 PM ET
    $FBRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Marketing Officer Suzuki Kentaro bought $5,960 worth of shares (4,000 units at $1.49) (SEC Form 4)

    4 - Nautilus Biotechnology, Inc. (0001808805) (Issuer)

    11/10/25 9:29:14 PM ET
    $NAUT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $ACRX
    $BBLG
    $CYTO
    $DMTK
    SEC Filings

    View All

    Bone Biologics Corp filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - Bone Biologics Corp (0001419554) (Filer)

    3/13/26 4:35:42 PM ET
    $BBLG
    Industrial Specialties
    Health Care

    SEC Form 424B5 filed by Bone Biologics Corp

    424B5 - Bone Biologics Corp (0001419554) (Filer)

    3/13/26 4:31:10 PM ET
    $BBLG
    Industrial Specialties
    Health Care

    SEC Form 10-K filed by IN8bio Inc.

    10-K - IN8BIO, INC. (0001740279) (Filer)

    3/12/26 4:15:58 PM ET
    $INAB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ACRX
    $BBLG
    $CYTO
    $DMTK
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CEO, President, and Secretary Patel Sujal M bought $65,238 worth of shares (25,000 units at $2.61), increasing direct ownership by 0.24% to 10,366,721 units (SEC Form 4)

    4 - Nautilus Biotechnology, Inc. (0001808805) (Issuer)

    3/4/26 6:37:20 PM ET
    $NAUT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form 4 filed by CFO and Treasurer Mowry Anna

    4 - Nautilus Biotechnology, Inc. (0001808805) (Issuer)

    3/4/26 5:31:36 PM ET
    $NAUT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form 4 filed by Chief Scientist Mallick Parag

    4 - Nautilus Biotechnology, Inc. (0001808805) (Issuer)

    3/4/26 5:31:31 PM ET
    $NAUT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $ACRX
    $BBLG
    $CYTO
    $DMTK
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Evercore ISI initiated coverage on Forte Biosciences with a new price target

    Evercore ISI initiated coverage of Forte Biosciences with a rating of Outperform and set a new price target of $65.00

    11/25/25 8:42:19 AM ET
    $FBRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Guggenheim initiated coverage on Forte Biosciences with a new price target

    Guggenheim initiated coverage of Forte Biosciences with a rating of Buy and set a new price target of $75.00

    8/18/25 8:56:30 AM ET
    $FBRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    TD Cowen initiated coverage on Forte Biosciences

    TD Cowen initiated coverage of Forte Biosciences with a rating of Buy

    1/21/25 7:45:55 AM ET
    $FBRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACRX
    $BBLG
    $CYTO
    $DMTK
    Leadership Updates

    Live Leadership Updates

    View All

    Nautilus Biotechnology Appoints Proteomics Commercial Leader Amber Faust as Vice President of Sales

    SEATTLE, March 02, 2026 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ:NAUT), a company pioneering single-molecule proteome analysis, today announced the appointment of Amber Faust as Vice President of Sales. Ms. Faust joins Nautilus following the public debut of the Nautilus Voyager™ Platform, designed to deliver and scale Iterative Mapping, a method that enables single-molecule analysis of proteins and proteoforms across the proteome. Ms. Faust brings nearly two decades of commercial leadership experience in life sciences, with a focus on advancing adoption of emerging proteomics technologies across pharmaceutical, biotechnology, academic, clinical, and government sectors. S

    3/2/26 8:00:00 AM ET
    $NAUT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Bone Biologics Appoints Phillip T. Meikle to its Board of Directors

    Brings 30+ years of commercial experience in the orthopedic and spine industry Bone Biologics Corporation ("Bone Biologics" or the "Company") (NASDAQ:BBLG, BBLGW))), a developer of orthobiologic products for spine fusion markets, announces the appointment of Phillip T. Meikle to the Company's board of directors, effective immediately. Mr. Meikle succeeds Don R. Hankey, who retired from the Board following seven years of service. The number of directors of Bone Biologics remains at four. Mr. Meikle most recently was president and chief executive officer of Biosystems of New England, Inc., an orthopedic distribution company that he founded in 1992 and sold to Stryker Corporation in 2019. He

    10/21/24 8:00:00 AM ET
    $BBLG
    Industrial Specialties
    Health Care

    Altamira Therapeutics to Host First Half 2024 Financial Results and Business Update Call on September 24, 2024

    Hamilton, Bermuda, Sept. 20, 2024 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. ("Altamira" or the "Company") (NASDAQ:CYTO), a company providing nanoparticle-based technology for efficient RNA delivery to extrahepatic targets, today announced that it will host its First Half 2024 Financial Results and Business Update Call on Tuesday, September 24, 2024. Founder, Chairman, and CEO Thomas Meyer and COO Covadonga Pañeda will deliver prepared remarks followed by a Q&A session where they will address questions from investors and analysts. Webcast Access: Event: Altamira Therapeutics First Half 2024 Financial Results and Business Update CallDate: Tuesday, September 24, 2024Time: 8:30 am ET We

    9/20/24 9:01:00 AM ET
    $CYTO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACRX
    $BBLG
    $CYTO
    $DMTK
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Forte Biosciences Inc.

    SC 13G/A - Forte Biosciences, Inc. (0001419041) (Subject)

    12/6/24 4:05:50 PM ET
    $FBRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Bone Biologics Corp

    SC 13G/A - Bone Biologics Corp (0001419554) (Subject)

    11/14/24 7:19:34 PM ET
    $BBLG
    Industrial Specialties
    Health Care

    Amendment: SEC Form SC 13G/A filed by Forte Biosciences Inc.

    SC 13G/A - Forte Biosciences, Inc. (0001419041) (Subject)

    11/14/24 4:31:51 PM ET
    $FBRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACRX
    $BBLG
    $CYTO
    $DMTK
    Financials

    Live finance-specific insights

    View All

    Nautilus Biotechnology Reports Fourth Quarter and Fiscal Year 2025 Financial Results

    SEATTLE, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ:NAUT), a company pioneering a single-molecule proteome analysis platform, today reported financial results for the fourth quarter and fiscal year ended December 31, 2025. Fourth Quarter 2025 and Fiscal Year 2025 Business Highlights Continued progress was made in processing and analyzing Tau proteoform samples from collaborators to support platform validation and expanding scientific publications. Externally generated Tau data measured on the Nautilus Voyager™ platform was presented at the World HUPO conference, and collaborators are advancing results toward submission for publication.Further progress was made

    2/26/26 8:00:00 AM ET
    $NAUT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Nautilus Biotechnology to Announce Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026

    SEATTLE, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ:NAUT, or "Nautilus")), a company pioneering a single-molecule protein analysis platform, today announced it will report financial results for the fourth quarter and full year 2025 before market open on Thursday, February 26, 2026. The company's management will webcast a corresponding conference call beginning at 5:30 a.m. Pacific Time / 8:30 a.m. Eastern Time to discuss its results, business developments, and outlook. Live audio of the webcast will be available on the "Investors" section of the company website at: www.nautilus.bio. About Nautilus Biotechnology, Inc.With its corporate headquarters in Seattle,

    2/5/26 8:00:00 AM ET
    $NAUT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Nautilus Biotechnology Reports Third Quarter 2025 Financial Results

    SEATTLE, Oct. 28, 2025 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ:NAUT, or "Nautilus")), a company pioneering a single-molecule proteome analysis platform, today reported financial results for the third quarter ended September 30, 2025. Third Quarter 2025 Business Highlights Continued progress was made in processing Tau proteoform samples from collaborators in support of our goals of product validation and growing our publications. We expect to share this data at the upcoming World HUPO conference.Further progress was made in the development of a new broadscale assay format, which is intended to support our forthcoming commercial launch in late 2026.We expect to launch our

    10/28/25 8:00:00 AM ET
    $NAUT
    Biotechnology: Laboratory Analytical Instruments
    Industrials